For the non-responder patients in the same cohort, we still saw an increase in CD8 communication (the sum of all expected arc counts involving CD8 was 0.0817 before treatment vs. 0.175 on treatment), but not in tumor communication (0.5588 vs. 0.5223) upon ICB treatment. This evidence concerns the gene CD8A and neoplasm.